Adenomyosis Market Size was valued at USD 0.12 Billion in 2023. The Global Adenomyosis industry is projected to grow from USD 0.17 Billion in 2024 to USD 1.02 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.495% during the forecast period (2024 - 2032).
The adenomyosis market is majorly driven by the high prevalence of urinary tract infections, rise in fibroid removal surgeries, increasing infection rates, rising population of women aged 40 and above, rising demand for technical advancements, increasing number of regulatory approvals, and growing penetration by market players. Additionally, factors such as the increasing funding for research and development initiatives in advanced medical treatment options are likely to drive the market. However, factors such as lack of awareness regarding causes and symptoms of adenomyosis are likely to hamper the growth of the market.
The adenomyosis market is segmented on the basis of type, treatment, diagnosis, and end-user. Considering type, the market is segmented into focal, adenomyoma, and diffuse. With reference to treatment, the market is segmented into anti-inflammatory drugs, hormone medications, and hysterectomy.
By anti-inflammatory drugs, the market is sub-segmented into ibuprofen and naproxen. By hormone medications, the market is segmented into combined estrogen-progestin pills, vaginal rings, hormone-containing patches, and aromatase inhibitors. Based on diagnosis, the market is segmented into ultrasound, MRI, historiography, hysteroscopy, cystoscopy, and laparoscopy.
By end-user, the market is segmented into hospitals and clinics, research institutes and ambulatory surgical centers, and others. Based on region, the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
North America is expected to hold the largest share of the adenomyosis market during the forecast period 2018–2023. The increasing prevalence of urinary tract infection is likely to enhance the growth of adenomyosis. Additionally, factors such as increasing government initiatives and funding for research and development in advanced medical treatment options along with the rising demand for technologically advanced treatments are likely to enhance the growth of the adenomyosis market in North America. For instance, according to the National Institute of Diabetes and Digestive and Kidney Diseases, urinary infections are the most common bladder infections, and at least 40 to 60%of women develop a UTI during their lifetime.
Adenomyosis is a disease that occurs in women during their childbearing years. This disease is said to affect the mid-aged women and women who have had children. Women aged 40 and above are more prone to contract adenomyosis. According to the American U.S. Bureau, in 2016, around 10.57 million women were aged 40 and above. Additionally, according to the Government of Canada, in 2014 Canadas’ population comprised of 17.9 million females. This huge population of women aged 40 and above is expected to have a direct effect on the adenomyosis market as adenomyosis is known to affect mid-age women.
Europe is the second largest market and is expected to hold a healthy share in the adenomyosis market during the forecast period 2018–2023. The European market is expected to grow at a strong growth rate during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with the growing need for better healthcare infrastructure. Furthermore, increasing older women population along with the increasing prevalence of urinary infections is driving the growth of the adenomyosis market in Europe.
Asia Pacific is expected to be the fastest growing market. Factors such as the increasing prevalence of inflammatory disorders and injuries are the major drivers for the market growth. China is expected to be the fastest growing country due to increasing population and raising awareness about the health and availability of new treatment methods. Moreover, rising healthcare expenditure and improvement in the standard of living are driving the growth of the adenomyosis market in the Asia Pacific region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the development of the healthcare industry and rising availability of specialty care centers.
Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, technology assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
North America
South America
Europe
Asia Pacific
Middle East and Africa
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | USD 1.02 Billion by 2032 |
| CAGR | 4.49% (2024 - 2032) |
| Base Year | 2023 |
| Forecast Period | 2024 - 2032 |
| Historical Data | 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Types, end user, Region |
| Geographies Covered | America, Europe, Asia Pacific, Middle East and Africa |
| Key Vendors | Bayer AG, Novartis AG, Pfizer, Inc., Johnson & Johnson Services, Inc., Siemens Healthcare Scientific Ltd., Ferring B.V., Merck KGaA, Specialty European Pharma, Urit Medical Electronic Group Co., Ltd, Roche Diagnostics, Danaher Corporation, Sysmex Corporation, Acon Laboratories, Inc., Mindray Medical International Limited, Arkray, Inc., Elektronika Kft. |
Adenomyosis Market Highlights:
Frequently Asked Questions (FAQ) :
Major treatments for adenomyosis include hormone medications and anti-inflammatory drugs.
Global adenomyosis market is expected to exhibit a strong 4.49% CAGR over the forecast period from 2024 to 2032.
The rising prevalence of urinary tract infections is the major driver for the adenomyosis market.
North America holds the largest share in the adenomyosis market.
Leading players in the adenomyosis market include Bayer, Novartis, and Pfizer, among others.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
